Elevated Plasma Adrenomedullin Levels in Patients with Unresectable Advanced Gastrointestinal Cancers
Authors:
- Yoshinori OzonoYOYoshinori Ozono
- Hotaka TamuraHTHotaka Tamura
- Kazuo KitamuraKKKazuo Kitamura
- Ayumu HosokawaAHAyumu Hosokawa
- Yukiko OtsukiYOYukiko Otsuki
- Hiroshi HatadaHHHiroshi Hatada
- Naomi UchiyamaNUNaomi Uchiyama
- Satoshi ShimamotoSSSatoshi Shimamoto
- Koji IgarashiKIKoji Igarashi
- Hiroshi KawakamiHKHiroshi Kawakami
Open Access
- 10 September 2026
- journal article
- research article
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 8 (3) , 54
Abstract
Background/Objectives: Adrenomedullin (AM) is a circulating peptide involved in tumor progression, angiogenesis, and fibrosis. However, its clinical utility as a biomarker in gastrointestinal cancers remains unclear. Methods: This single-center prospective observational study included patients with unresectable advanced gastrointestinal cancers (esophageal, gastric, colorectal, biliary tract, and pancreatic cancers) and healthy volunteers. Plasma AM levels were measured before the initiation of systemic chemotherapy in patients with cancer and at the time of enrollment in healthy volunteers. Results: In the unadjusted analyses, plasma mature and total AM levels were significantly higher in the cancer group than in healthy volunteers. Age was significantly associated with both mature and total AM levels, whereas sex did not show a significant association. After adjustment for age, between-group differences in mature and total AM levels were not statistically significant. Among patients with pancreatic cancer, plasma mature and total AM levels were significantly higher in stage IV than in stage III disease. Conclusions: Higher plasma AM levels were observed in the cancer group than in healthy controls in the unadjusted analyses; however, these differences were not statistically significant after adjustment for age. A stage-related difference was observed in pancreatic cancer. These findings should be considered hypothesis-generating and require validation in larger studies with appropriately matched control groups.Keywords
This publication has 14 references indexed in Scilit:
- Advances and Challenges in Pluripotent Stem Cell‐Based Whole‐Cell Vaccines for Cancer TreatmentMedicine Bulletin, 2025
- Nucleic acid drug and delivery techniques for disease therapy: Present situation and future prospectInterdisciplinary Medicine, 2024
- Adrenomedullin in Heart Failure: Pathophysiology and Therapeutic ApplicationEuropean Journal of Heart Failure, 2018
- Adrenomedullin Is Expressed in Pancreatic Cancer and Stimulates Cell Proliferation and Invasion in an Autocrine Manner via the Adrenomedullin Receptor, ADMRCancer Research, 2007
- Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesisOncogene, 2003
- The Effects of Adrenomedullin Overexpression in Breast Tumor CellsJNCI: Journal of the National Cancer Institute, 2002
- Increased Plasma Levels of Adrenomedullin in Patients with Systemic Inflammatory Response SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 1999
- High levels of circulating adrenomedullin in severe illness: Correlation with C-reactive protein and evidence against the adrenal medulla as site of originExperimental and Clinical Endocrinology & Diabetes, 1997
- Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure.Journal of Clinical Investigation, 1994
- Adrenomedullin: A Novel Hypotensive Peptide Isolated from Human PheochromocytomaBiochemical and Biophysical Research Communications, 1993